REG — Vulcan Two Group PLC — Notice of Results and Investor Presentation

For best results when printing this announcement, please click on link below: RNS Number: 0403W Vulcan Two Group PLC 24 September 2026 24 September 2026 Vulcan Two Group plc (the “Company”, "Group" or "Vulcan Two") Notice of Results and Investor Presentation Vulcan Two Group plc, the Company building a leading regulated UK ePharmacy through buy and build, will announce its Half Year Results on Tuesday 29 September 2026. Following the release of the results, the Company’s management team will be hosting a live presentation at 11am (BST) on 29 September 2026 via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders and registration can be completed via the following Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation. com) (Financial PR) Tel: +44 (0) 20 3405 0205 Justine James / Sam Modlin / Will Merison Notes to Editors Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated ePharmacy platform, through its disciplined buy-and-build strategy.

Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets. The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit This information is provided by RNS, the news service of the London Stock Exchange.

RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. com) or visit ( ). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.

For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy ( ). END NORSEFFLDEMSEIU